CSIMarket
 
Novocure Limited  (NVCR)
Other Ticker:  
 
 
Price: $13.9800 $-0.63 -4.312%
Day's High: $14.655 Week Perf: -12.57 %
Day's Low: $ 13.91 30 Day Perf: -10.5 %
Volume (M): 1,261 52 Wk High: $ 83.60
Volume (M$): $ 17,634 52 Wk Avg: $31.45
Open: $14.48 52 Wk Low: $10.87



 Market Capitalization (Millions $) 1,484
 Shares Outstanding (Millions) 106
 Employees 1,000
 Revenues (TTM) (Millions $) 509
 Net Income (TTM) (Millions $) -207
 Cash Flow (TTM) (Millions $) 127
 Capital Exp. (TTM) (Millions $) 27

Novocure Limited
Novocure Limited is a medical technology company that develops and commercializes innovative cancer treatments based on the combination of electric fields and chemotherapy to disrupt cancer cell division. The company was founded in 2000, and its headquarters are located in Jersey, United Kingdom. It operates with a team of over 1000 employees worldwide, including the United States, Switzerland, Japan, Israel, and Germany, among other countries.

Novocure aims to improve the lives of cancer patients by providing innovative, non-invasive cancer therapies that improve survival rates while maintaining the patient's quality of life. Its primary product, the Optune system, is an FDA-approved device that delivers Tumor Treating Fields (TTFields) to cancer cells, interrupting their division without the toxic side effects of chemotherapy. TTFields use low-intensity electric fields to inhibit cancer cell division, resulting in a slower tumor growth rate and better survival outcomes.

The company's products are used to treat brain tumors, mesothelioma, pancreatic cancer, and non-small cell lung cancer. Novocure has conducted extensive clinical trials on its products, engaging in over 12 clinical trials with a total of over 2000 patients, reporting positive results. The company has also published over 50 peer-reviewed articles showing the efficacy of its Optune system.

Apart from its product pipeline, Novocure has established collaborations with several renowned academic institutions worldwide, including Columbia University, Dartmouth College, and the Mayo Clinic. The company's clinical and R&D teams work closely with these institutions to advance research and clinical studies on cancer treatments.

Novocure Limited aims to become a world leader in cancer care by providing innovative cancer therapies that enhance patient outcomes and reduce treatment-related side effects. The company continues to invest in research & development and clinical studies to further expand the use of Tumor Treating Fields and improve cancer care globally.


   Company Address: No. 4 The Forum St. Helier 0
   Company Phone Number: 3475 6700   Stock Exchange / Ticker: NASDAQ NVCR
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Novocure Limited

Novocure Limited Reports Higher Losses but Modest Revenue Growth in Latest Financial Results

Novocure Limited, a biomedical firm specializing in oncology treatments, recently announced its financial results for the October to December 2023 period. While the company reported a net loss per share of $-0.43 compared to $-0.35 the previous year, its revenue increased by 4.17% to $133.78 million. However, Novocure's revenue growth is lagging behind its peers in the Medical Equipment & Supplies industry, which reported a 7.21% increase in revenue during the same period.
In the previous quarter, Novocure achieved revenue of $127.32 million and a net loss per share of $-0.46. For the October to December 2023 interval, the company's net shortfall amounted to $-47.079 million, higher than the $-37.303 million recorded a year ago. Additionally, Novocure's inventories and supplies have seen a noticeable increase to $38.2 million, higher than in the previous and corresponding quarters. On the other hand, the level of accounts receivable has declined to $61.2 million, leading some analysts to suggest that demand may be slowing down.

Product Service News

FDA Accepts Novocure's Premarket Approval Application for NSCLC Therapy in Promising Medical Breakthrough

Published Thu, Jan 18 2024 12:00 PM UTC

Biomedical firm Novocure (NASDAQ: NVCR) has announced the U.S. Food and Drug Administration?s (FDA) acceptance for filing of its Premarket Approval (PMA) application. The PMA is focused on procuring authorization for the use of Tumor Treating Fields (TTFields) therapy jointly with standard systemic therapies to treat non-small cell lung cancer (NSCLC), after a patient has ex...

Business Update

Novocure's Optune Gio: A Beacon of Hope in the Battle Against Newly Diagnosed Glioblastoma

Published Tue, Jan 9 2024 12:00 PM UTC

Novocure's Optune Gio Shows Promise in Phase 3 TRIDENT Trial for Newly Diagnosed Glioblastoma PatientsIn a groundbreaking development in the fight against glioblastoma (GBM), Novocure, a Swiss-based global oncology company, announced today the successful enrollment of the final patient in its phase 3 TRIDENT clinical trial. This trial aims to evaluate the safety and efficacy...

Management Changes

Novocure's New Chief Medical Officer Joins Forces to Tackle Financial Headwinds

Published Thu, Jan 4 2024 9:05 PM UTC


Novocure, a leading global oncology company, has recently named Dr. Nicolas Leupin as their new Chief Medical Officer (CMO). Dr. Leupin's appointment comes at a crucial time for the company as it seeks to navigate both medical and financial challenges. With a strong background in the biotechnology and pharmaceutical industries, as well as extensive experience as a medic...

Product Service News

Novocure to Unveil Groundbreaking TTFields Therapy Data at SNO Annual Meeting, Amidst Competitor Challenges

Published Fri, Nov 10 2023 1:00 PM UTC


Novocure is set to make significant presentations on its Tumor Treating Fields (TTFields) therapy, which includes new clinical data and real-world evidence. The research will be unveiled at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting in Vancouver, Canada, from November 16th to November 19th. Novocure plans to showcase information from the phase 2 2-THE-TOP ...






 

Novocure Limited's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Novocure Limited does not provide revenue guidance.

Earnings Outlook
Novocure Limited does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com